FDA Grants Expanded Access to Promising Pancreatic

Why Is Pancreatic Cancer So Difficult to Treat?

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is notoriously difficult to detect early because the pancreas sits deep within the abdomen and symptoms are often vague until the disease has spread. According to the American Cancer Society, the majority of patients are diagnosed at advanced stages, when surgical resection — the only potentially curative treatment — is no longer an option. By that point, tumors have often invaded surrounding blood vessels or metastasized to the liver, lungs, or peritoneum.

The biology of pancreatic tumors also poses unique therapeutic challenges. The cancer is encased in a dense fibrotic microenvironment known as desmoplastic stroma, which physically obstructs the delivery of chemotherapy agents and limits immune cell infiltration. Standard regimens such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel offer modest survival benefits, but resistance develops quickly. This therapeutic landscape is why expanded access to investigational drugs carries particular weight for the pancreatic cancer community.

What Does FDA Expanded Access Actually Mean for Patients?

The FDA's expanded access program is a regulatory pathway that permits use of an unapproved drug for treatment outside of a clinical trial when a patient has a serious or immediately life-threatening illness and there are no satisfactory approved options. The program requires that the potential benefit justify the potential risks and that providing the drug not interfere with ongoing clinical investigations needed to support approval. Physicians must apply on behalf of patients, and the drug's manufacturer must agree to provide the medication.

For pancreatic cancer patients, expanded access can be the difference between exhausting options and gaining months of additional treatment. However, expanded access is not a substitute for full FDA approval — efficacy data continue to be collected through clinical trials, and access does not guarantee benefit. Insurers may not cover investigational drugs or associated costs, and patients should discuss with oncologists whether enrollment in a clinical trial — which provides more rigorous monitoring — might be a better fit before pursuing expanded access.

How Are Newer Pancreatic Cancer Therapies Working?

Recent therapeutic advances have shifted toward precision oncology. Patients whose tumors harbor BRCA1 or BRCA2 mutations may benefit from PARP inhibitors such as olaparib, which the FDA approved as maintenance therapy for metastatic pancreatic cancer with germline BRCA mutations. KRAS-targeted therapies, long considered impossible due to the protein's structure, have made progress with drugs targeting specific KRAS G12C and G12D mutations that are common in pancreatic tumors.

Other investigational approaches include stromal-disrupting agents designed to break down the dense tumor microenvironment, novel immunotherapy combinations, and antibody-drug conjugates that deliver cytotoxic payloads directly to cancer cells. National Cancer Institute–supported research continues to explore early detection biomarkers, recognizing that earlier diagnosis remains one of the most powerful tools to improve survival.